CDIP‐2, a synthetic peptide derived from chemokine (C‐C motif) ligand 13 (CCL13), ameliorates allergic airway inflammation
Airway inflammation is characterized by selective recruitment of mononuclear and granulocytic cells. This recruitment is mediated by the action of chemotactic cytokines, such as chemokines. A number of chemokines and their receptors have been identified and proposed as potential therapeutic agents in allergic airway inflammation. One of these chemokines is chemokine (C‐C motif) ligand 13 (CCL13), a CC chemokine that has been associated with allergic inflammatory diseases such as asthma and allergic rhinitis. To investigate alternative therapeutic agents to alleviate allergic inflammatory diseases, a number of chemokine‐derived synthetic peptides were designed and tested for their ability to modulate in vitro and in vivo chemokine‐mediated functions. Our results show that one of these peptides, CDIP‐2, displayed antagonist functions in in vitro chemotaxis assays using monocytic cell lines. In addition, we found that CDIP‐2 significantly reduced peribronchial, perivascular infiltrate and mucus overproduction in an ovalbumin‐induced allergic lung inflammation murine model. Thus, CDIP‐2 may be considered as part of a novel group of anti‐inflammatory agents based on chemokine‐derived synthetic peptides.